The Cancer News
AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Artificial Intelligence to Facilitate Cancer Care
By Dr. Brenda Santellano
**By Dr. Brenda Santellano -** **Research Associate at Georgia Cancer Center** [Dr. Jospeph Finkelstein, MD, PhD, FAMIA, FACMI](https://medicine.utah.edu/faculty/joseph-finkelstein) explored the tra...
Artificial Intelligence to Facilitate Cancer Care
By Dr. Brenda Santellano
**By Dr. Brenda Santellano -** **Research Associate at Georgia Cancer Center** [Dr. Jospeph Finkelstein, MD, PhD, FAMIA, FACMI](https://medicine.utah.edu/faculty/joseph-finkelstein) explored the tra...
Artificial Intelligence to Facilitate Cancer Care
By Dr. Brenda Santellano
**By Dr. Brenda Santellano -** **Research Associate at Georgia Cancer Center** [Dr. Jospeph Finkelstein, MD, PhD, FAMIA, FACMI](https://medicine.utah.edu/faculty/joseph-finkelstein) explored the tra...
Best Practices in Supporting LGBTQ+ Communities
By Editorial Team
At The Summit on Cancer Health Disparities 2024, in the session titled “Best Practices in Serving LGBTQ+ Communities,” Nakita Venus (they/them) and Elle Brooks (she/they) from Seattle’s LGBTQ Center, ...
Best Practices in Supporting LGBTQ+ Communities
By Editorial Team
At The Summit on Cancer Health Disparities 2024, in the session titled “Best Practices in Serving LGBTQ+ Communities,” Nakita Venus (they/them) and Elle Brooks (she/they) from Seattle’s LGBTQ Center, ...
Best Practices in Supporting LGBTQ+ Communities
By Editorial Team
At The Summit on Cancer Health Disparities 2024, in the session titled “Best Practices in Serving LGBTQ+ Communities,” Nakita Venus (they/them) and Elle Brooks (she/they) from Seattle’s LGBTQ Center, ...
Antibody Drug Conjugates
By Editorial Team
_**Author**: **Dr. Arya Mariam** **Roy** from Roswell Park Comprehensive Cancer Center_ **What are antibody drug conjugates (ADCs)?** Antibody drug conjugates (ADCs) are newer targeted medicines...
Antibody Drug Conjugates
By Editorial Team
_**Author**: **Dr. Arya Mariam** **Roy** from Roswell Park Comprehensive Cancer Center_ **What are antibody drug conjugates (ADCs)?** Antibody drug conjugates (ADCs) are newer targeted medicines...
Antibody Drug Conjugates
By Editorial Team
_**Author**: **Dr. Arya Mariam** **Roy** from Roswell Park Comprehensive Cancer Center_ **What are antibody drug conjugates (ADCs)?** Antibody drug conjugates (ADCs) are newer targeted medicines...
Authors' Take: Consequences of Cancer Diagnosis in India
By Editorial Team
This week, The Cancer News had the opportunity to connect with three authors (Dr. Aju Mathew, Sruti Ranganathan, and Dr. Edward Christopher Dee) of a recent article in the peer-reviewed Journal **Supp...
Authors' Take: Consequences of Cancer Diagnosis in India
By Editorial Team
This week, The Cancer News had the opportunity to connect with three authors (Dr. Aju Mathew, Sruti Ranganathan, and Dr. Edward Christopher Dee) of a recent article in the peer-reviewed Journal **Supp...
Authors' Take: Consequences of Cancer Diagnosis in India
By Editorial Team
This week, The Cancer News had the opportunity to connect with three authors (Dr. Aju Mathew, Sruti Ranganathan, and Dr. Edward Christopher Dee) of a recent article in the peer-reviewed Journal **Supp...
ASCO23 - WU-KONG6 Trial Summary
By Editorial Team
**Author:** Lei Deng, MD Roswell Park Comprehensive Cancer Center _**Live report from ASCO23, Chicago, IL**_ June 6, 2023 **[9002](https://meetings.asco.org/abstracts-presentations/220375) Sunvoze...
ASCO23 - WU-KONG6 Trial Summary
By Editorial Team
**Author:** Lei Deng, MD Roswell Park Comprehensive Cancer Center _**Live report from ASCO23, Chicago, IL**_ June 6, 2023 **[9002](https://meetings.asco.org/abstracts-presentations/220375) Sunvoze...
ASCO23 - WU-KONG6 Trial Summary
By Editorial Team
**Author:** Lei Deng, MD Roswell Park Comprehensive Cancer Center _**Live report from ASCO23, Chicago, IL**_ June 6, 2023 **[9002](https://meetings.asco.org/abstracts-presentations/220375) Sunvoze...
ASCO23 – LUNAR Study Summary
By Editorial Team
**Author:** Lei Deng, MD [Roswell Park Comprehensive Cancer Center](https://www.roswellpark.org/) _**Live report from ASCO23, Chicago, IL**_ June 6, 2023 [**LBA9005**](https://meetings.asco.org/ab...
ASCO23 – LUNAR Study Summary
By Editorial Team
**Author:** Lei Deng, MD [Roswell Park Comprehensive Cancer Center](https://www.roswellpark.org/) _**Live report from ASCO23, Chicago, IL**_ June 6, 2023 [**LBA9005**](https://meetings.asco.org/ab...
ASCO23 – LUNAR Study Summary
By Editorial Team
**Author:** Lei Deng, MD [Roswell Park Comprehensive Cancer Center](https://www.roswellpark.org/) _**Live report from ASCO23, Chicago, IL**_ June 6, 2023 [**LBA9005**](https://meetings.asco.org/ab...
Adjuvant Ribociclib and Endocrine Therapy in Patients with HR+/HER2 Negative Early Breast Cancer: Phase III NATALEE Trial
By Editorial Team
By Dr. Shipra Gandhi from Roswell Park Comprehensive Cancer Center Findings from the MonarchE clinical trial1 led to the approval of combination abemaciclib with AI in the adjuvant setting for pat...
Adjuvant Ribociclib and Endocrine Therapy in Patients with HR+/HER2 Negative Early Breast Cancer: Phase III NATALEE Trial
By Editorial Team
By Dr. Shipra Gandhi from Roswell Park Comprehensive Cancer Center Findings from the MonarchE clinical trial1 led to the approval of combination abemaciclib with AI in the adjuvant setting for pat...
Adjuvant Ribociclib and Endocrine Therapy in Patients with HR+/HER2 Negative Early Breast Cancer: Phase III NATALEE Trial
By Editorial Team
By Dr. Shipra Gandhi from Roswell Park Comprehensive Cancer Center Findings from the MonarchE clinical trial1 led to the approval of combination abemaciclib with AI in the adjuvant setting for pat...
A Summary of the DACOTA Trial
By Editorial Team
By Dr. Chepsy Philip [Believer's Church Medical College Hospital](https://www.bcmch.org/) Myeloproliferative - Chronic Myelomonocytic Leukemia (MP-CMML), a subset in the rare patient population of C...
A Summary of the DACOTA Trial
By Editorial Team
By Dr. Chepsy Philip [Believer's Church Medical College Hospital](https://www.bcmch.org/) Myeloproliferative - Chronic Myelomonocytic Leukemia (MP-CMML), a subset in the rare patient population of C...
A Summary of the DACOTA Trial
By Editorial Team
By Dr. Chepsy Philip [Believer's Church Medical College Hospital](https://www.bcmch.org/) Myeloproliferative - Chronic Myelomonocytic Leukemia (MP-CMML), a subset in the rare patient population of C...
AEGEAN trial: A phase 3 study of Neoadjuvant Durvalumab plus Chemotherapy followed by Adjuvant Durvalumab versus Neoadjuvant Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer
By Editorial Team
By Dr. Dipesh Uprety [Karmanos Cancer Institute](https://www.karmanos.org/karmanos/karmanos-home) Four cycles of cisplatin-based adjuvant chemotherapy after surgical resection have remained the stan...
AEGEAN trial: A phase 3 study of Neoadjuvant Durvalumab plus Chemotherapy followed by Adjuvant Durvalumab versus Neoadjuvant Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer
By Editorial Team
By Dr. Dipesh Uprety [Karmanos Cancer Institute](https://www.karmanos.org/karmanos/karmanos-home) Four cycles of cisplatin-based adjuvant chemotherapy after surgical resection have remained the stan...
AEGEAN trial: A phase 3 study of Neoadjuvant Durvalumab plus Chemotherapy followed by Adjuvant Durvalumab versus Neoadjuvant Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer
By Editorial Team
By Dr. Dipesh Uprety [Karmanos Cancer Institute](https://www.karmanos.org/karmanos/karmanos-home) Four cycles of cisplatin-based adjuvant chemotherapy after surgical resection have remained the stan...
Zuma 7 trial shows statistically significant overall survival benefit for yescarta
By Editorial Team
By Dr. Luke Fletcher [Willamette Valley Cancer Institute & Research Center](https://www.oregoncancer.com/) _The Zuma 7 trial is a randomized, open-label multicenter study for patients with primary ref...
Zuma 7 trial shows statistically significant overall survival benefit for yescarta
By Editorial Team
By Dr. Luke Fletcher [Willamette Valley Cancer Institute & Research Center](https://www.oregoncancer.com/) _The Zuma 7 trial is a randomized, open-label multicenter study for patients with primary ref...
Zuma 7 trial shows statistically significant overall survival benefit for yescarta
By Editorial Team
By Dr. Luke Fletcher [Willamette Valley Cancer Institute & Research Center](https://www.oregoncancer.com/) _The Zuma 7 trial is a randomized, open-label multicenter study for patients with primary ref...